• Company
• Daewoong succeeds in Entresto's unregistered patent
• by Kim, Jin-Gu Mar 28, 2023 05:56am

• Company
• Sam Chun Dang Pharm’s biosimilar equivalent to Eylea
• by Nho, Byung Chul Mar 28, 2023 05:56am

• Company
• Erleada's reimb and lower coinsurance rate raise issue
• by Eo, Yun-Ho Mar 28, 2023 05:56am

• Opinion
• [Reporter's view] The goal of global new drug development
• by Hwang, Jin-joon Mar 28, 2023 05:54am

• Opinion
• [Reporter's view] Tagrisso's first benefit
• by Mar 27, 2023 05:56am

• Company
• Pfizer Korea dividend KRW 12.48M, net profit KRW 119.5B
• by Chon, Seung-Hyun Mar 27, 2023 05:56am

• Policy
• Jeil Pharmaceutical discontinued Actos co-promotion
• by Lee, Tak-Sun Mar 27, 2023 05:56am

• Company
• SGLT-2 combo Qtern awaits release in Korea
• by Eo, Yun-Ho Mar 27, 2023 05:56am

• Policy
• Dupixent 200mg, newly listed
• by Kim, Jung-Ju Mar 27, 2023 05:55am

• Policy
• Forxiga patent is about to expire
• by Kim, Jung-Ju Mar 24, 2023 05:48am